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Proteases that are released during inflammation and injury cleave protease-activated receptor 2
(PAR2) on primary afferent neurons to cause neurogenic inflammation and hyperalgesia.
PAR2-induced thermal hyperalgesia depends on sensitization of transient receptor potential
vanilloid receptor 1 (TRPV1), which is gated by capsaicin, protons and noxious heat. However,
the signalling mechanisms by which PAR2 sensitizes TRPV1 are not fully characterized. Using
immunofluorescence and confocal microscopy, we observed that PAR2 was colocalized with
protein kinase (PK) Cε and PKA in a subset of dorsal root ganglia neurons in rats, and that PAR2
agonists promoted translocation of PKCε and PKA catalytic subunits from the cytosol to the
plasma membrane of cultured neurons and HEK 293 cells. Subcellular fractionation and Western
blotting confirmed this redistribution of kinases, which is indicative of activation. Although PAR2
couples to phospholipase Cβ, leading to stimulation of PKC, we also observed that PAR2 agonists
increased cAMP generation in neurons and HEK 293 cells, which would activate PKA. PAR2
agonists enhanced capsaicin-stimulated increases in [Ca2+]i and whole-cell currents in HEK 293
cells, indicating TRPV1 sensitization. The combined intraplantar injection of non-algesic doses
of PAR2 agonist and capsaicin decreased the latency of paw withdrawal to radiant heat in mice,
indicative of thermal hyperalgesia. Antagonists of PKCε and PKA prevented sensitization of
TRPV1 Ca2+ signals and currents in HEK 293 cells, and suppressed thermal hyperalgesia in
mice. Thus, PAR2 activates PKCε and PKA in sensory neurons, and thereby sensitizes TRPV1 to
cause thermal hyperalgesia. These mechanisms may underlie inflammatory pain, where multiple
proteases are generated and released.
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Protease-activated receptor 2 (PAR2) is widely expressed
in the nervous system where it mediates the actions
of proteases on diverse neuronal processes (reviewed
in Ossovskaya & Bunnett, 2004). Proteases from the
circulation (coagulation factors VIIa, Xa; Camerer et al.
2000), inflammatory cells (tryptase; Corvera et al.
1997; Molino et al. 1997), epithelial cells and neurons
(trypsins I, II, IV; Cottrell et al. 2004) can cleave PAR2
to expose a tethered ligand domain that binds to and
activates the cleaved receptor. Activated PAR2 controls
neurogenic inflammation, pain and neuronal excitability.
PAR2 is expressed by primary spinal afferent neurons,
where activation stimulates release of substance P and
calcitonin gene-related peptide in peripheral tissues to
cause neurogenic inflammation (Steinhoff et al. 2000;
Cenac et al. 2002, 2003; Nguyen et al. 2003). Similar
mechanisms mediate the effects of PAR2 agonists on
airway constriction (Ricciardolo et al. 2000) and gastric
mucus secretion (Kawabata et al. 2001b). PAR2 agonists
also cause thermal and mechanical somatic hyperalgesia
(Kawabata et al. 2001a; Vergnolle et al. 2001), and
excite mesenteric sensory neurons to induce visceral
hyperalgesia (Hoogerwerf et al. 2001; Coelho et al.
2002; Kirkup et al. 2003). However, the molecular
mechanisms by which PAR2 regulates neuronal functions
are incompletely understood.
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PAR2-induced thermal hyperalgesia depends on
sensitization of transient potential receptor vanilloid 1
(TRPV1) (Amadesi et al. 2004; Dai et al. 2004).
TRPV1 is a non-selective cation channel expressed by
nociceptive neurons, that mediates inflammatory and
thermal hyperalgesia (Caterina et al. 1997, 2000; Davis
et al. 2000). Exogenous (capsaicin, ethanol) and endo-
genous (protons pH < 6.0, heat > 43◦C, anandamide)
factors directly activate TRPV1 (Caterina et al. 1997;
Zygmunt et al. 1999; Trevisani et al. 2002). In addition,
PAR2 agonists (Amadesi et al. 2004; Dai et al. 2004) and
other inflammatory agents, including bradykinin, ATP,
prostaglandin E2 (PGE2) and nerve growth factor (NGF)
(Lopshire & Nicol, 1997; Chuang et al. 2001; Tominaga
et al. 2001; Vellani et al. 2001) indirectly sensitize TRPV1,
causing hyperalgesia. The mechanisms of this sensitization
include activation of protein kinase (PK) C and PKA,
which phosphorylate TRPV1 to modify channel gating
(Lopshire & Nicol, 1998; Premkumar & Ahern, 2000;
Bhave et al. 2002; Mohapatra & Nau, 2003). The PKCε iso-
zyme, which plays a major role in mechanical and thermal
hyperalgesia (Khasar et al. 1999), phosphorylates TRPV1
(Numazaki et al. 2002) to mediate bradykinin-induced
sensitization of TRPV1 currents (Cesare et al. 1999). PKA,
a mediator of injury-induced hyperalgesia (Malmberg
et al. 1997), also phosphorylates TRPV1 to regulate its
desensitization (Bhave et al. 2002; Mohapatra & Nau,
2003), and thereby mediates PGE2-induced sensitization
of TRPV1 (Lopshire & Nicol, 1998; Rathee et al. 2002).
Additional mechanisms of TRPV1 sensitization include
altered interactions of TRPV1 with the endogenous
inhibitor phosphatidylinositol-4,5-bisphosphate (Chuang
et al. 2001; Prescott & Julius, 2003), and PKC- and Src
kinase-dependent trafficking of TRPV1 to the plasma
membrane (Morenilla-Palao et al. 2004; Zhang et al.
2005).
The purpose of the present investigation was to define
the mechanisms by which PAR2 sensitizes TRPV1 to
induce thermal hyperalgesia. Although PKCε contributes
to PAR2-induced sensitization of TRPV1 currents (Dai
et al. 2004), the role of PKCε in PAR2-induced
thermal hyperalgesia has not been examined, and the
contributions of other second messenger kinases, such
as PKA, are unknown. Our objectives were to determine
whether (1) primary spinal afferent neurons that express
PAR2 also contain PKCε and PKA, using immuno-
fluorescence and confocal microscopy; (2) PAR2 agonists
activate and cause membrane translocation of PKCε
and PKA in neurons and cell lines, using micro-
scopy, subcellular fractionation and Western blotting;
(3) PKCε and PKA mediate PAR2-induced sensitization
of TRPV1 in cell lines, by measuring TRPV1 Ca2+
signals and currents; and (4) PKCε and PKA mediate
PAR2-induced sensitization of TRPV1-dependent thermal
hyperalgesia.
Methods
Animals
Sprague-Dawley rats (male, 200–250 g) and C57Bl6
mice (male, 6–8 weeks) were obtained from Charles
River Laboratories (CA, USA, and Canada). The study
was approved by Institutional Animal Care and Use
Committees of the University of California, San Francisco
and the University of Calgary. At the end of the experiments
animals were humanely killed using sodium pentobarbital
(200 mg kg−1 i.p.) and bilateral thoracotomy.
Agonists and antagonists
PAR2-activating peptide (PAR2-AP, SLIGRL-NH2),
corresponding to the tethered ligand of rat and mouse
PAR2, and the inactive reverse peptide sequence
(PAR2-RP), which was used as the control, were
obtained from Sigma Genosys (The Woodlands, TX,
USA). Bovine pancreatic trypsin was from Worthington
Biochemical Corporation (Lakewood, NJ, USA). The
selective PKCε translocation inhibitor peptide
(EAVSLKPT, PKCεI), inactive scrambled sequence
(PKCεI-sc), the PKA inhibitor H-89 (N-[2-((p-bromo-
cinnamyl)amino)ethyl]-5-isoquinolinesulphonamide),
cell-permeable myristoylated PKA inhibitor 14–22
amide (PKAI14-22, Myr-GRTGRRNAI-NH2), and
the PKA activator forskolin were from Calbiochem
(La Jolla, CA, USA). The PKC activators phorbol
12-myristate 13-acetate (PMA) and phorbol dibutyrate,
and indomethacin, a cyclo-oxygenase inhibitor,
were from Sigma (St Louis, MO, USA). The PKA
inhibitor WIPTIDE (TTYADFIASGRTGRRNAI-NH2)
was from Peninsula Laboratories (San Carlos, CA,
USA). The PKCεI conjugated to TAT protein to
promote membrane permeability (Schwarze et al.
1999) (TAT-PKCεI, YGRKKRRQRRRC-disulphide
bond-CEAVSLKPT-COOH) and the inactive scrambled
sequence (TAT-PKCεI-sc) were from SynPep Corp
(Dublin, CA, USA). The selection of inhibitors and doses
used in this study was based on previous studies (Aley
et al. 2000, 2001; Hu et al. 2002; Rathee et al. 2002).
Antibodies
Rabbit anti-human PKCε, rabbit anti-human PKAα
catalytic subunit (PKAC), mouse anti-human PAR2
(SAM11) and mouse anti-EGFP (enhanced green
fluorescent protein) were from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). Goat anti-rabbit and
anti-mouse IgG conjugated to FITC, Rhodamine Red X
or horseradish peroxidase were from Jackson Immuno-
Research (West Grove, PA, USA). In control experiments,
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primary antibodies were incubated before use with
peptides used for immunization (1 μm, 24 h, 4◦C).
Cell lines
Human embryonic kidney (HEK) 293 cells were
maintained in modified Eagle’s with Earle’s BSS medium
(MEM), 10% fetal bovine serum (FBS) and 100 U ml−1
penicillin, 0.1 mg ml−1 streptomycin. HEK 293 cells stably
expressing human TRPV1 (HEK-TRPV1, a gift from Dr J.
Davis, GSK Harlow, UK) were generated and maintained
in MEM, 10% FBS and geneticin (400 mg l−1) (Hayes et al.
2000). HEK-FLP cells (Invitrogen, Carlsbad, CA, USA)
stably expressing human PAR2 with N-terminal Flag and
C-terminal T7 epitopes (HEK-PAR2) were generated and
maintained as described (Jacob et al. 2005). HEK 293 cells
were transiently transfected with 1 μg of EGFP-human
PKCε (a gift from Dr Daria Mochly Rosen, Stanford
University) using Lipofectamine 2000. (Invitrogen) to
generate HEK-PKCε-EGFP cells (Schechtman et al. 2004).
These cells were studied 48 h after transfection.
Neuronal culture
Rats were anaesthetized with sodium pentobarbital
(200 mg kg−1 i.p.). Dorsal root ganglia (DRG) from the
thoracic and lumbar spinal cord were removed and
minced in cold Hank’s balanced salt solution (HBSS) and
incubated for 60–90 min at 37◦C in Dulbecco’s modified
Eagle’s medium (DMEM) containing 0.5 mg ml−1 of
trypsin, 1 mg ml−1 of collagenase type IA and 0.1 mg ml−1
of DNase type IV (Sigma) (Steinhoff et al. 2000).
Soybean trypsin inhibitor (Sigma) was added to neutralize
trypsin. Neurons were pelleted, suspended in DMEM
containing 10% FBS, 10% horse serum, 100 U ml−1
penicillin, 0.1 mg ml−1 streptomycin, 2 mm glutamine and
2.5 μg ml−1 DNase type IV, plated on glass coverslips
coated with Matrigel (BD Biosciences, Bedford, MA, USA),
and cultured for 2–3 days.
Localization of PKCε and PKAC in cultured cells
HEK 293 cells and cultured DRG neurons were incubated
in HBSS, 0.1% BSA, 20 mm Hepes, pH 7.4 at 37◦C and
treated with test substances. Cells were fixed with 4%
paraformaldehyde, 100 mm PBS, pH 7.4 for 20 min at 4◦C.
Cultured cells were incubated with PBS containing 5–10%
normal goat serum and 0.1–0.3% Triton X-100 for 30 min,
and incubated with primary antibodies to PKCε (1 : 250)
or PKAC (1: 400) for 16 h at 4◦C. After washing, cells were
incubated with goat anti-rabbit IgG conjugated to FITC
(1 : 300) for 2 h at room temperature. Cells expressing
PKCε-EGFP were similarly treated and fixed.
Localization of PKCε, PKAC and PAR2 in DRG sections
Rats (male, 200 g) were anaesthetized with sodium pento-
barbital (200 mg kg−1 i.p.) and transcardially perfused
with PBS containing 100 U of heparin, followed by 4%
paraformaldehyde in 100 mm PBS, pH 7.4. DRG (L4–L6)
were immersion fixed for 4 h at 4◦C. DRG were incubated
in 20% sucrose in PBS for 24 h at 4◦C, embedded in
OCT compound (Miles, Elkhart, IN, USA), and frozen
sections of 16 μm were prepared. Sections were incubated
with PBS containing 5–10% normal goat serum and
0.1–0.3% Triton X-100 for 30 min, and incubated with
primary antibodies: PKCε (1 : 750), PKAC (1 : 750), PAR2
(1 : 250) for 16 h at 4◦C. After washing, sections were
incubated with goat anti-rabbit IgG conjugated to FITC
or goat anti-mouse IgG conjugated to Rhodamine Red X
(1 : 200) for 2 h at room temperature. Slides were washed
and mounted in Prolong (Molecular Probes, Eugene, OR,
USA).
Confocal microscopy
Specimens were observed using Zeiss Axiovert and
Bio-Rad MRC1000 confocal microscopes with Zeiss Plan
Apo ×40 (NA 1.4) or ×100 (NA 1.3) objectives. Images
were collected at zoom of 1–2, iris of < 3 μm and typically
5–10 optical sections were taken at intervals of 0.5 μm.
Images were coloured to represent the appropriate fluoro-
phores, and processed using Adobe Photoshop 7.0 (Adobe
Systems, Mountain View, CA, USA) to adjust contrast
and brightness. Images of stained and control slides were
collected and processed identically. To quantify the effects
of agonists on the subcellular distribution of PKCε and
PKAC in cultured neurons, the fluorescence intensity of
the cells was measured by selecting a straight line across
the neuronal soma and using the plot profile function of
ImageJ software (version 10.2, NIH image). The averaged
fluorescence intensities between peripheral and central
regions of the cell were compared. The number of neurons
showing redistribution of these kinases between the
cytosol and periphery of the cells was also determined and
expressed as a percentage of the total number of neurons
analysed.
Subcellular fractionation and Western blotting
HEK 293 cells were maintained overnight in MEM and
0.1% BSA. Cells were incubated in HBSS, 0.1% BSA,
20 mm Hepes, pH 7.4 and treated at 37◦C for 0–10 min
with PAR2 agonists. Cells were washed with ice-cold PBS,
scraped into 150 μl of homogenization buffer (20 mm
Tris-HCl, pH 7.4 and protease inhibitors) and disrupted
with 20 strokes in a glass homogenizer. The lysate
was centrifuged at 500 g for 10 min, and the resulting
supernatant was centrifuged at 100 000 g for 1 h. The
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supernatant was collected as the cytosolic fraction. The
pellet containing the membrane fraction was treated with
lysis buffer (1% SDS, 20 mm Tris-HCl, pH 7.4 and protease
inhibitor cocktail, Roche Diagnostics, Indianapolis, IN,
USA). Both cytosolic and membrane fractions were boiled
for 5 min and clarified by centrifugation at 15 000 g
for 15 min. Protein concentration was measured by
BCA assay. Samples (5 μg protein) were separated by
SDS-PAGE (8% for PKCε, 12% for PKAC). Proteins were
transferred to PVDF membranes (Millipore, Billerica,
MA, USA). Membranes were incubated overnight at 4◦C
with antibodies to PKCε (1 : 10 000), PKAC (1 : 10 000)
or EGFP (1 : 10 000) in PBS containing 5% milk powder,
2% BSA, 0.1% Tween-20. Membranes were washed and
incubated with goat anti-rabbit or anti-mouse horse-
radish peroxidase (1 : 10 000) for 1 h at room temperature.
Immunoreactive proteins were detected by Enhanced
Chemiluminescence (Pierce, Rockford, IL, USA). To
ensure equal loading, membranes were stained with
amido-black to detect all proteins.
Measurement of intracellular calcium
concentration ([Ca2+]i)
The experimental procedure has been previously described
(Amadesi et al. 2004). HEK 293 cells were incubated
in HBSS, 0.1% BSA, 20 mm Hepes, pH 7.4, containing
2.5 μm of fura-2/AM (Invitrogen) for 30–45 min at 37◦C.
Coverslips were mounted in an open chamber (350 μl)
at 37◦C. Fluorescence of individual cells was measured
at 340 nm and 380 nm excitation and 510 nm emission
using a Zeiss Axiovert microscope, an ICCD video camera
(Stanford Photonics, Stanford, CA, USA) and a video
microscopy acquisition program (Axon Instruments, Inc.,
Union City, CA, USA). Test substances were directly added
to the chamber (50 μl injection). Each coverslip received
only one treatment with PAR2-AP or RP followed by
capsaicin. In some experiments cells were pretreated for
30 min at 37◦C with inhibitors before challenging with
test substances. The magnitude of capsaicin responses was
calculated as the increase above baseline. Results were first
calculated as the 340 nm/380 nm emission ratio, which
is proportional to the [Ca2+]i, and then expressed as a
percentage of the potentiation observed in cells pretreated
with PAR2-AP and antagonist vehicle (100%).
Measurement of intracellular cAMP
HEK 293 cells were maintained overnight in MEM-0.1%
BSA. HEK 293 cells and DRG neurons in culture
were incubated in HBSS, 0.1% BSA, 20 mm Hepes,
pH 7.4 and treated with PAR2 agonists for 0–5 min at
37◦C. Intracellular cAMP levels were measured using
the cAMP enzyme immunoassay system following the
non-acetylation protocol according to the manufacturer’s
directions (Amersham Bioscience, Bucks, UK).
Electrophysiology
The experimental procedure has been previously described
(Amadesi et al. 2004) with slight modifications. Membrane
currents of HEK 293 cells were recorded using an
Axopatch 1D amplifier (Axon Instruments). Patch pipette
resistance ranged from 1 to 3 M, and the holding
potential was −60 mV. The pipette solution was (mm):
KCl 140, MgCl2 1, EGTA 5, Hepes 5, and ATPNa2 5.
The external solution was (mm): NaCl 140, CaCl2 2,
KCl 4, MgCl2 1, glucose 11, Hepes 5 and CsCl 3. The
pH was adjusted with either KOH (pipette solution,
pH 7.2) or NaOH (external solution, pH 7.4). In these
standard solutions the input resistance of the HEK 293 cells
was 1–10 G. Whole-cell currents were recorded using
Axotape software and analysed using Axograph software
(Axon Instruments). Membrane potentials were corrected
for the liquid junction potential (pipette −11 mV). The
recording chamber was continuously superfused with
the external solution at approximately 2 ml min−1. Rapid
application of agonists in the external solution was made
using an eight-barrelled fast-flow device (Barajas-Lopez
et al. 1994). Experiments were at room temperature
(∼23◦C). Control TRPV1 responses were obtained by
repeated application of capsaicin (300 nm) for ∼20 s.
Only neurons that did not exhibit desensitization to
two consecutive capsaicin applications were selected for
the study. PAR2-AP (100 μm) or, in a small series of
experiments, the PKC agonist phorbol dibutyrate (300 nm)
was then applied for 2 min and TRPV1 responses were
examined at 30 s to 18 min following PAR2 activation.
Results were expressed as a percentage of the control
TRPV1 current. In some experiments, PKCε translocation
inhibitor peptide or H89 was added to the pipette solution.
Paw withdrawal latency
Test substances were administered by intraplantar
injection in mice under light halothane (5%) anaesthesia
(Vergnolle et al. 2001). PAR2-AP, PAR2-RP, PKCε and
PKA inhibitors were dissolved in physiological saline
(0.9% NaCl); capsaicin was dissolved in 80% physio-
logical saline, 10% ethanol, and 10% Tween 80. To
allow the entry of the membrane-impermeant inhibitors
into cells, injection of PKCεI, PKCεI-sc and WIPTIDE
(all 2.5 μl paw−1) was preceded by injection of distilled
water (2.5 μl paw−1) to cause a transient hyposmotic
permeabilization. Mice received an intraplantar injection
of PAR2-AP and capsaicin (5 μl paw−1) 15–30 min later
(final volume 10 μl paw−1). The latency of paw withdrawal
to a radiant heat stimulus was measured before and after
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the intraplantar injections of test substances, using a
plantar test apparatus (Ugo Basile, Milan, Italy). Thermal
hyperalgesia was defined as a decrease in the withdrawal
latency compared to the basal measurement.
Statistical analysis
Results are expressed as mean ± s.e.m. Comparisons
between groups were made by ANOVA and the Bonferroni
test, Student’s t test, or a paired Student’s t test to evaluate
differences between the same cells. Comparisons between
proportions were made using Primer of Biostatistics
software (3.1 version, Macintosh version, McGraw Hill,
1992) and the ‘standard error of proportion’ and the
‘compare two proportions’ functions. Differences were
considered significant when P ≤ 0.05.
Figure 1. Localization of immunoreactive PAR2, PKCε and PKAC in DRG neurons
A and D, PAR2; B, PKCε; E, PKAC; C and F, merge. G, PKCε preabsorption control; H, PKAC preabsorption control.
Neurons expressing PAR2 also expressed PKCε and PKAC (arrows). Scale bar = 20 μm.
Results
DRG neurons that express PAR2 also contain PKCε
and PKAC
PAR2 is present in DRG neurons that express
substance P, calcitonin gene-related peptide and TRPV1,
and which therefore mediate neurogenic inflammation
and nociception (Steinhoff et al. 2000; Amadesi et al. 2004).
To determine if PAR2-expressing neurons also contain the
potential regulatory kinases PKCε and PKAC, we used
immunofluorescence. Immunoreactive PAR2 was present
in small- and medium-diameter neurons that are typically
considered nociceptive neurons (Fig. 1A and D). These
neurons also contained immunoreactive PKCε and PKAC
(Fig. 1B, C, E and F , arrows). Staining for PKCε and PKAC
was abolished by preabsorption of the antibodies with
the peptides used for immunization, suggesting specificity
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(Fig. 1G and H). Since PAR2 and TRPV1 are coexpressed
in nociceptive neurons (Amadesi et al. 2004), PKCε and
PKAC are appropriately localized to mediate PAR2-induced
regulation of TRPV1.
PAR2 agonists activate PKCε in HEK 293 cells
and DRG neurons
PKCε phosphorylates and sensitizes TRPV1 (Numazaki
et al. 2002). We investigated the effects of PAR2 agonists
on translocation of PKCε from the cytosol to the plasma
membrane, since membrane translocation of PKCε is
an index of activation of this kinase (Dorn & Mochly
Rosen, 2002). We first studied trafficking of PKCε-EGFP
expressed in HEK 293 cells, which can be detected with
high sensitivity and specificity. PAR2 agonists sensitize
TRPV1 similarly in HEK 293 cells and DRG neurons
(Amadesi et al. 2004). Thus, HEK 293 cells, which naturally
express PAR2, are a useful model system to study regulation
of TRPV1. In unstimulated HEK 293 cells, PKCε-EGFP
was detected in the cytosol (Fig. 2A). PMA (1 μm), a
PKC activator, induced a prominent redistribution of
PKCε-EGFP from the cytosol to the plasma membrane at
5 min (Fig. 2A). In a similar manner, PAR2-AP (100 μm)
induced trafficking of PKCε-EGFP to the membrane
within 0.5 min and 1 min (Fig. 2A), and after 15 min
PKCε-EGFP returned to the cytosol (results not shown).
PAR2-RP (100 μm, 1 min) did not affect the subcellular
distribution of PKCε-EGFP (Fig. 2A). PMA and PAR2-AP
also stimulated membrane translocation of immuno-
reactive PKCε in HEK-TRPV1 cells (results not shown).
Thus, EGFP does not interfere with the redistribution
of PKCε to the plasma membrane. Of note, PAR2-AP
also caused translocation of PKCε-EGFP to the nucleus
after 1 min (Fig. 2A). However, we did not detect nuclear
translocation of endogenous PKCε after exposure to
PAR2-AP (not shown). Thus, the physiological relevance
of this redistribution is unknown.
We also examined the effects of PMA and PAR2 agonists
on the subcellular localization of immunoreactive PKCε
in rat DRG neurons in culture. Since the effects of agonists
on PKCε trafficking in neurons were less prominent than
in HEK 293 cells, we measured the pixel intensity of
signals in the central (cytosol) and peripheral (membrane)
regions of the soma, and also determined the proportion
of neurons in which there was detectable redistribution of
PKCε. In unstimulated neurons, immunoreactive PKCε
was predominantly diffusely localized in the cytosol
(Fig. 2B). The PKCε signal was most intense in the cytosol,
with minimal signal at the plasma membrane (Fig. 2C).
Indeed, PKCε was detected at the plasma membrane
of only 3 ± 5% of the unstimulated neurons (n = 318
total neurons) (Fig. 2D). PMA (1 μm, 5 min) induced
a prominent redistribution of PKCε from the cytosol
to the plasma membrane of neurons (Fig. 2B and C),
and now membrane staining was detected in 99 ± 2%
of neurons (n = 176) (Fig. 2D). PAR2-AP (100 μm) also
induced trafficking of PKCε to the plasma membrane
within 0.5 min (14 ± 4% of n = 196), with a maximal
effect at 1 min (62 ± 3% of n = 125) (Fig. 2B–D). At 5 min,
PKCε was still localized at the membrane (77 ± 5% of
n = 142), but the staining was more diffuse, suggesting
return to the cytosol (not shown). PAR2-RP (100 μm)
had no effect on the localization of PKCε, with < 15% of
neurons having detectable PKCε at the plasma membrane
(9 ± 3% of n = 104 at 0.5 min and 12 ± 3% of n = 152 at
1 min) (Fig. 2B–D).
To confirm that PAR2 activation induces membrane
translocation of PKCε in HEK 293 cells, and to determine
the kinetics of this process, we quantified PKCε in
cytosolic and membrane fractions by Western blotting.
In unstimulated HEK-PKCε-EGFP cells, PKCε-EGFP
was predominantly in cytosolic fractions (Fig. 3A and
B). After incubation with PAR2-AP (100 μm), the
level of PKCε-EGFP increased in membrane fractions
and diminished in cytosolic fractions within 0.5–1 min
(Fig. 3A and B). PAR2-AP also caused translocation
of endogenous immunoreactive PKCε from cytosolic
to membrane fractions of HEK-TRPV1 cells within
1 min (Fig. 3C and D). PKCε-EGFP was still detected
in membrane fractions 10 min after PAR2 activation,
when endogenous PKCε had returned to the cytosol. The
more persistent presence of PKCε-EGFP in membrane
fractions may reflect the higher sensitivity of detection of
PKCε-EGFP, or be due to the over-expression of PKCε, or
be related to an effect of EGFP on association of PKCε
with the membrane. Trypsin (10 nm) caused a similar
membrane translocation of PKCε-EGFP and immuno-
reactive PKCε in HEK 293 cells (not shown). We did
not quantify membrane translocation of PKCε in DRG
neurons by Western blotting, due to the limited number
of cells and the low levels of PKCε expression. Together, our
results show that agonists of PAR2 induce redistribution
of PKCε to the plasma membrane in both HEK 293 cells
and DRG neurons, suggesting activation of PKCε.
PAR2 agonists activate PKA in DRG neurons
and HEK 293 cells
TRPV1 has been proposed as a target for the cAMP/PKA
cascade, and PKA phosphorylates TRPV1 to regulate
its desensitization (Bhave et al. 2002; Rathee et al.
2002). Exposure of sensory neurons to forskolin, which
activates the cAMP/PKA cascade, induces translocation
of the PKAC to the cell periphery, which is indicative
of activation (Rathee et al. 2002). To determine if PAR2
agonists activate PKA, we examined their effects on the
subcellular distribution of PKAC in DRG neurons. In most
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Figure 2. Effects of PAR2 agonist on the subcellular distribution of PKCε determined by confocal micro-
scopy
A, HEK 293 cells expressing PKCε-EGFP (enhanced green fluorescent protein). In unstimulated cells (non-treated,
NT), PKCε-EGFP was cytosolic and in vesicles (arrows). PMA (phorbol 12-myristate 13-acetate) induced translocation
to the plasma membrane at 5 min (arrowheads). PAR2-AP induced translocation to the plasma membrane at 1 min
(arrowheads). PAR2-RP did not affect the subcellular location of PKCε-EGFP, which remained in the cytosol and
vesicles (arrows). Scale bar = 10 μm. B, rat DRG neurons in culture. In unstimulated neurons (NT, non-treated),
PKCε was cytosolic and in vesicles (arrows). PMA induced translocation of PKCε to the plasma membrane at
5 min (arrowheads). PAR2-AP also induced translocation of PKCε to the plasma membrane at 0.5 and 1 min
(arrowheads). PKCε was in the cytosol and vesicles of cells treated with PAR2-RP (arrows). Control shows staining
with preabsorbed PKCε antibody. Scale bar = 10 μm. C, fluorescence intensity (in arbitrary units) measured in
a line bisecting the neuronal soma (e.g. see dashed line in B). In untreated cells (NT) or cells incubated with
PAR2-RP (1 min), the signal was mostly cytosolic. In cells treated with PMA (5 min) or PAR2-AP (1 min), the signal
in the cytosol diminished and was more prominent at the plasma membrane. Each trace is an average of 4–6 cells.
D, the effect of PMA, PAR2-AP and PAR2-RP on the percentage of the total number of observed neurons expressing
PKCε with PKCε either in the cytosol or at the plasma membrane of the soma. The proportion of cells with PKCε
at the plasma membrane was increased after treatment with PMA and PAR2-AP. Observations from n > 100 cells.
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unstimulated neurons, immunoreactive PKAC was
cytosolic or present in vesicles that were uniformly
distributed throughout the cytoplasm (Fig. 4A). This
uniform cytosolic distribution of PKAC was confirmed
by measuring the pixel intensity (Fig. 4B). Indeed, PKAC
was detected in the vicinity of the plasma membrane in
only 22 ± 5% of unstimulated neurons (of n = 270 total
neurons) (Fig. 4C). Forskolin (10 μm, 0.5 min), which
activates PKA, stimulated the redistribution of PKAC from
the central to the peripheral region of the cell (Fig. 4A).
This redistribution was confirmed by measurement of
the pixel intensity of immunoreactive PKAc (Fig. 4B).
This peripheral staining of PKAc was detected in 92 ± 2%
of neurons (n = 141) (Fig. 4C). PAR2-AP (100 μm) also
stimulated the redistribution of PKAC from the central
to the peripheral regions of the soma, and this effect was
observed in 70 ± 4% of neurons at 1 min (n = 143), and
76 ± 3% of neurons at 5 min (n = 205) after stimulation
(Fig. 4A–C). After 10–15 min, PKAC returned to cytosolic
vesicles (not shown). In contrast, PAR2-RP had no effect
on the subcellular distribution of immunoreactive PKAC,
with only 15 ± 4% of neurons showing localization of
PKAC close to the plasma membrane at 5 min (n = 106)
(Fig. 4A–C).
To confirm that PAR2 activation induces membrane
translocation of PKAC in HEK-TRPV1 cells, which endo-
genously express PKA regulatory and catalytic subunits
Figure 3. Effects of PAR2 agonist on the subcellular distribution of PKCε in HEK 293 cells determined by
subcellular fractionation and Western blotting
A, Western blot, and B, densitometric analysis of PKCε-EGFP (enhanced green fluorescent protein) in cytosolic
(c) and membrane (m) fractions of HEK-PKCε-EGFP cells. PAR2-AP increased PKCε-EGFP in membrane fractions
and decreased PKCε-EGFP in cytosolic fractions. C, Western blot, and D, densitometric analysis of immunoreactive
PKCε in cytosolic and membrane fractions of HEK-TRPV1 cells. PAR2-AP increased PKCε in membrane fractions
and decreased PKCε in cytosolic fractions. ∗P < 0.05 compared to 0 min, n = 4 experiments.
(Rathee et al. 2002), we quantified PKAC in cytosolic and
membrane fractions by Western blotting. After 1 min of
incubation with PAR2-AP (100 μm), there were elevated
levels of PKAC in membrane fractions, and diminished
levels in cytosolic fractions (Fig. 5A and B). Thus, PAR2
agonists cause translocation of PKAC from the cytosol to
membrane fractions, which is indicative of activation of
PKA.
It is well established that PAR2 couples to Gαq/11,
resulting in activation of phospholipase Cβ and formation
of inositol trisphosphate and diacylglycerol, which
mobilize intracellular Ca2+ ions and activate PKC.
However, PAR2 agonists elevate cAMP levels in
keratinocytes (Scott et al. 2003), which suggests that PAR2
may activate the PKA cascade. Therefore, we determined
the effects of PAR2 agonists on cAMP levels in HEK-PAR2
cells and DRG neurons. PAR2-AP (100 μm) and trypsin
(10 nm) increased the cAMP levels in HEK-PAR2 cells by
∼35% within 1 and 5 min, whereas PAR2-RP (100 μm)
had no effect (Fig. 5C). Similarly, PAR2-AP (100 μm)
and trypsin (10 nm) increased the cAMP levels in rat
DRG neurons by 40–60% after 5 min, whereas PAR2-RP
was inactive (Fig. 5C). PAR2 agonists caused a similar
increase of cAMP level in HEK-TRPV1 cells (not shown).
Since PAR2 agonists can stimulate the generation of
prostaglandins (Kong et al. 1997), which could activate
receptors that couple to form cAMP, we determined
C© 2006 The Authors. Journal compilation C© 2006 The Physiological Society
J Physiol 575.2 PAR2-mediated TRPV1 sensitization 563
whether inhibitors of cyclo-oxygenase prevented the
effects of PAR2 agonists on cAMP levels. Indomethacin
(5 μm) did not affect PAR2-AP or trypsin-stimulated
formation of cAMP in HEK 293 cells (not shown). Thus,
agonists of PAR2 induce redistribution of PKAC and
increase cAMP levels in neurons and cells, suggesting an
activation of the cAMP/PKA cascade.
Figure 4. Effects of PAR2 agonist on the subcellular distribution of PKAC determined by confocal micro-
scopy in rat DRG neurons in culture
A, unstimulated neuron (non-treated, NT), PKAC (PKA catalytic subunit) was in vesicles and uniformly distributed
throughout the cytosol (arrows). Forskolin (FSK) induced redistribution of PKAC from the central to the peripheral
region of the soma at 0.5 min (arrows). PAR2-AP also induced redistribution of PKAC to the peripheral region of the
cell at 1 min and 5 min (arrows). PKAC was uniformly distributed in the cytosol and in vesicles of cells treated with
PAR2-RP (arrows). Control shows staining with preabsorbed PKAC antibody. Scale bar = 10 μm. B, fluorescence
intensity (in arbitrary units) measured in a line bisecting the neuronal soma (e.g. see dashed line in A). In untreated
cells (NT) or cells incubated with PAR2-RP (5 min), the signal was mostly cytosolic. In cells treated with FSK (0.5 min)
or PAR2-AP (5 min), the signal in the cytosol diminished and was more prominent in superficial regions of the soma.
Each trace is an average of 4–6 cells. C, the effects of FSK, PAR2-AP and PAR2-RP on the percentage of the total
number of observed neurons expressing PKAC with PKAC either in the cytosol or near the plasma membrane of
the soma. The proportion of cells with PKA in a superficial region of the cytosol was increased after treatment with
FSK and PAR2-AP. Observations from n > 100 cells.
PAR2 agonists sensitize TRPV1-mediated Ca2+
responses and TRPV1 currents by PKCε- and
PKA-dependent mechanisms
We have previously reported that PAR2 agonists sensitize
TRPV1 Ca2+ signals and currents in HEK 293 cells and
DRG neurons by mechanisms that require activation of
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phospholipase Cβ and PKC (Amadesi et al. 2004). We now
used selective inhibitors of PKCε and of PKA to determine
their contributions to PAR2-induced sensitization of
TRPV1. HEK-TRPV1 cells were used for these experiments
in view of the similar effects of PAR2 agonists on activation
of PKCε and PKA and sensitization of TRPV1 in both
HEK 293 cells and DRG neurons (Amadesi et al. 2004).
Exposure of HEK-TRPV1 cells to PAR2-AP (100 μm,
5 min) potentiated the effects of capsaicin (10 nm) on
[Ca2+]i by ∼70% (n = 131 cells), indicative of TRPV1
sensitization (Fig. 6A and B). In contrast, PAR2-RP
Figure 5. Effects of PAR2 agonists on the subcellular distribution
of PKAC (catalytic subunit) in HEK 293 cells and on cAMP levels
A, Western blot, and B, densitometric analysis of PKAC in cytosolic (c)
and membrane (m) fractions of HEK-TRPV1 cells. PAR2-AP caused an
increase in PKAC in membrane fractions and a decrease in cytosolic
fractions. ∗P < 0.05 compared to 0 min, n = 4 experiments. C, effects
of PAR2 agonists on cAMP level in HEK-PAR2 cells (left) and DRG
neurons (right). Try. = trypsin. PAR2-AP and trypsin caused an increase
in cAMP levels after 1 and 5 min. n = 3 experiments. ∗P < 0.05
compared to non-treated cells (NT), ∗∗∗P < 0.05 compared to PAR2-RP.
(100 μm, 5 min) had no effect. Pretreatment with
TAT-PKCεI (10 μm) prevented this sensitization (Fig. 6B).
Thus, the effect of capsaicin in cells treated with
TAT-PKCεI and PAR2-AP was 56 ± 7% (n = 116 cells)
of the responses in cells treated with PAR2-AP and
vehicle (100%). Pretreatment with inactive TAT-PKCεI-sc
(10 μm) had no effect on PAR2-AP-induced sensitization
of TRPV1 (n = 110 cells). Pretreatment with two selective
inhibitors of PKA, H-89 (10 μm) and the cell-permeable
PKAI14-22 (0.1 μm), also prevented PAR2-AP-mediated
sensitization of TRPV1 (Fig. 6B). The effect of capsaicin
in cells treated with H-89 and PAR2-AP was 62 ± 11%,
and in cells treated with PKAI14–22 and PAR2-AP was
53 ± 4% of the responses of cells treated with PAR2-AP
and vehicle (100%) (both n > 100 cells). Together,
these results suggest that activation of PAR2 sensitizes
TRPV1-mediated increases in [Ca2+]i by PKCε-and
PKA-dependent mechanisms.
By recording whole-cell currents in HEK-TRPV1 cells,
we found that pretreatment with PAR2-AP (100 μm)
resulted in a threefold increase in the current induced
by capsaicin (300 nm) applied 30 s later, indicative of
TRPV1 sensitization (Fig. 7A). This sensitization was
maximal when capsaicin was applied 3 min after PAR2-AP
when the capsaicin current was increased by 440%
(n = 10), and sensitization was sustained for at least
18 min (Fig. 7B). Repeated applications of capsaicin alone
over the same time period resulted in reproducible
responses, with no significant change in magnitude of
TRPV1 currents (n = 5; data not shown). Thus, TRPV1
did not desensitize in response to repeated challenges
with this concentration of capsaicin. When PKCεI
(200 μm) or H-89 (3 μm) were included in the pipette,
they markedly inhibited the PAR2-mediated sensitization
(Fig. 7C). Pretreatment with the PKC agonist phorbol
dibutyrate (300 nm) also sensitized TRPV1 currents,
causing a fourfold increase in capsaicin-evoked current
at 3 min. However, this sensitization was not inhibited
by H-89, demonstrating that the effect of H-89 did not
result from non-selective inhibition of PKC pathways
(phorbol dibutyrate = 429 ± 126% increase; phorbol
dibutyrate + H-89 = 685 ± 126% increase; n = 8). Thus,
PAR2 sensitizes TRPV1 currents in HEK-TRPV1 cells by
PKCε and PKA-dependent mechanisms.
PAR2 agonists sensitize TRPV1 to induce thermal
hyperalgesia by PKCε- and PKA-dependent
mechanisms
We have previously reported that the co-administration
of non-algesic doses of PAR2-AP and capsaicin induces
thermal hyperalgesia (Amadesi et al. 2004). Antagonism
or deletion of TRPV1 prevents this response, indicating
that PAR2 sensitizes TRPV1 to cause thermal hyperalgesia.
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Using the same experimental approach, we now sought
to investigate the role of PKCε and PKA in PAR2-induced
sensitization of TRPV1-dependent thermal hyperalgesia.
By measuring the paw withdrawal latency to radiant heat
in mice, we found that co-injection of non-algesic doses
of PAR2-AP (1 ng paw−1) and capsaicin (1 μg paw−1)
caused hyperalgesia, as indicated by a decrease in the
paw withdrawal latency (Fig. 8A and B). This hyperalgesia
was detected within 15 min and sustained for at least
120 min. Thus, as previously reported (Amadesi et al.
2004), PAR2-AP can sensitize TRPV1-induced thermal
hyperalgesia. To determine the contribution of PKCε and
PKA to this effect, we administered selective inhibitors
(Aley et al. 2000). Intraplantar injection of PKCεI
(1 μg paw−1), a selective inhibitor of PKCε translocation,
alone did not affect the basal withdrawal latency (Fig. 8A).
However, PKCεI strongly inhibited the hyperalgesic effect
of PAR2-AP and capsaicin at 15 and 30 min, and abolished
hyperalgesia at 60 and 120 min (Fig. 8A). The inactive
PKCεI-sc (1 μg paw−1) had no effect on the response
to co-injection of PAR2-AP and capsaicin (Fig. 8A).
Figure 6. Effects of PAR2 agonists on capsaicin-
induced Ca2+ signalling in HEK-TRPV1 cells
Cells were exposed to PAR2-AP or PAR2-RP for 5 min,
and then challenged with capsaicin. A, changes in
[Ca2+]i, with each line the average trace from
n = 31–35 cells. B, the effects of antagonists on
PAR2-induced sensitization of capsaicin responses
(100%). Veh = vehicle control. ∗P < 0.05 compared to
PAR2-AP/vehicle cells. n = 70–80 cells from 3
experiments.
The intraplantar injection of WIPTIDE (1 μg paw−1), a
selective PKA inhibitor, alone had no significant effect on
the basal withdrawal latency (Fig. 8B). However, WIPTIDE
abolished the hyperalgesic effect of PAR2-AP and capsaicin
at 30–120 min (Fig. 8B). Thus, PAR2 sensitizes TRPV1 to
induce thermal hyperalgesia by a mechanism that requires
activation of both PKCε and PKA.
Discussion
It is well established that certain proteases can cleave
PAR2 on sensory neurons to stimulate the release of
substance P and calcitonin gene-related peptide, thereby
causing neurogenic inflammation and both thermal and
mechanical hyperalgesia (Steinhoff et al. 2000; Vergnolle
et al. 2001). It is also known that PAR2-induced thermal
hyperalgesia is dependent on sensitization of TRPV1
(Amadesi et al. 2004; Dai et al. 2004). However, the
molecular mechanisms by which PAR2 sensitizes TRPV1 to
cause thermal hyperalgesia are not fully understood. Our
results show, for the first time, that (1) PAR2 is co-expressed
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with PKCε and PKA in small- and medium-diameter
primary sensory neurons that transmit pain; (2)
PAR2 agonists activate PKCε and PKA, causing their
translocation to the plasma membrane in cell lines
and DRG neurons and that PAR2 agonists activate the
cAMP/PKA cascade in these cells; (3) activation of PKCε
Figure 7. PKCε and PKA antagonists inhibit the PAR2-mediated
sensitization of TRPV1 currents in HEK-TRPV1 cells
A, whole-cell inward currents induced by capsaicin (300 nM) before
(left trace) and 3 min after (right trace) application of PAR2-AP for
2 min. B, summary of mean TRPV1 currents over time following
activation of PAR2 with PAR2-AP (100 μM; n ≥ 5 for each time point).
PAR2-AP sensitized the capsaicin-induced current in a time-dependent
manner; reaching its maximum value 3 min after PAR2-AP treatment
(P < 0.01; n = 10). Membrane current values are expressed as
percentage of the control current recorded prior to PAR2-AP
application (second control bar). In five control cells (first control bar),
capsaicin was applied for ∼20 s and re-applied 3 min later (second
control bar), demonstrating the consistency of the capsaicin response.
In another five control cells, capsaicin was only applied once before
application of PAR2-AP. C, TRPV1 sensitization by PAR2-AP
(Veh = vehicle control n = 10, at 3 min) was prevented by PKCε
(PKCεI, 200 μM, n = 5) and PKA (H89, 3 μM, n = 5) inhibitors.
∗P < 0.05.
and PKA is required for the PAR2-mediated sensitization of
TRPV1 Ca2+ signals and currents; and (4) PKCε and PKA
mediate PAR2-induced sensitization of TRPV1 in vivo, and
are thus responsible for the resultant thermal hyperalgesia.
Several observations from the current investigation
suggest that PAR2 agonists activate PKCε and PKA. We
found that small- to medium-diameter neurons, which
are known to express PAR2 and TRPV1 (Amadesi et al.
2004), also contain PKCε and PKA. By a combination
of confocal microscopy, subcellular fractionation and
Western blotting, we observed that PAR2 agonists
promoted translocation of PKCε and the catalytic subunit
of PKA, which represents the active subunit of the PKA
heterotetramer, from the cytosol to the plasma membrane
in both DRG neurons and HEK 293 cells. PMA and
forskolin, established activators of PKC and PKA, had
similar effects on the subcellular localization of these
kinases. Thus, translocation of kinases from the cytosol
to the plasma membrane can be used in our system as an
indicator of kinase activation. Our results show that PKCε
and PKAC are not only appropriately colocalized with
PAR2 and TRPV1 in nociceptive neurons, but that PAR2
activates these kinases. Our findings are consistent with
other reports of the localization of PAR2, PKCε and PKAC
in primary sensory neurons. PAR2 is expressed by> 50% of
small- to medium-diameter neurons of rat DRG (Steinhoff
et al. 2000), and PKCε is present in 90% (Khasar et al. 1999)
and PKAC in 50% (Rathee et al. 2002) of these neurons. We
found that PAR2 agonists caused redistribution of kinases
in ∼60% of cells expressing PKCε and in ∼80% of cells
expressing PKA.
It is well established that PAR2 couples to Gαq/11,
resulting in activation of phospholipase Cβ and generation
of 1,4,5-inositol trisphosphate and diacylglycerol, which
would be expected to mobilize intracellular Ca2+ ions and
activate PKC (Ossovskaya & Bunnett, 2004). Therefore,
PAR2-induced activation of PKCε is consistent with the
known signalling pathway of this receptor. Moreover, our
results are in line with observations that agonists of PAR2
induce activation and membrane translocation of PKCε
in prostate stromal cells (Myatt & Hill, 2005). Given the
predominant coupling of PAR2 to Gαq/11, the observation
that PAR2 agonists caused membrane translocation of
PKAC was unanticipated. However, we observed that
PAR2 agonists stimulated generation of cAMP in DRG
neurons and HEK 293 cells, suggesting that PAR2 activates
the cAMP/PKA cascade. Our results are in agreement
with the observations that PAR2 agonists elevate cAMP
levels in keratinocytes (Scott et al. 2003), and that PAR2
activation causes release of von Willebrand factor in
endothelial cells by a PKA-dependent mechanism (Cleator
et al. 2006). Thus, PAR2, like PAR1, may couple to
different heterotrimeric G proteins and thereby regulate
multiple signalling pathways, including mobilization of
intracellular Ca2+ ions and generation of cAMP
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(Ossovskaya & Bunnett, 2004). Alternatively, PAR2
agonists could induce release of mediators that act in
an autocrine manner to generate cAMP and activate
PKA. One possible mediator is PGE2, since PAR2
agonists promote PGE2 release from epithelial cells (Kong
et al. 1997) and PGE2 sensitizes TRPV1 through a
PKA-dependent mechanism (Lopshire & Nicol, 1998;
Rathee et al. 2002). However, we found that indomethacin
did not prevent the effects of PAR2 agonists on cAMP
generation. Further studies are thus required to determine
the mechanism by which PAR2 agonists activate PKA in
neurons.
Upon translocation to the plasma membrane, activated
PKCε and PKA may phosphorylate and thereby sensitize
ion channels that participate in nociception, such as
TRPV1. Several observations from our investigation
support this possibility. Firstly, we observed that PAR2
agonists sensitized capsaicin-induced increases in [Ca2+]i
and capsaicin currents in HEK-TRPV1 cells, and we
and others have previously reported similar sensitization
in DRG neurons (Amadesi et al. 2004; Dai et al.
2004). Secondly, the co-injection of non-algesic doses
of PAR2 and capsaicin induced sustained thermal
Figure 8. Mechanisms of PAR2-induced potentiation of
TRPV1-mediated thermal hyperalgesia
Compounds were injected into the paws of mice, and
hyperalgesia was measured as a significant decrease in
withdrawal latency in response to a thermal stimulus,
compared to basal (time 0). A, effects of the PKCε inhibitor
(PKCεl) alone or on PAR2-AP and capsaicin-induced
hyperalgesia. B, effects of the PKA inhibitor (WIPTIDE) alone
or on PAR2-AP and capsaicin-induced hyperalgesia. Controls
include use of inactive PKCεl-sc or the WIPTIDE vehicle.
n = 8 mice per group, ∗P < 0.05 compared to basal values.
hyperalgesia, which we have shown to depend on
sensitization of TRPV1 (Amadesi et al. 2004). Finally,
selective antagonists of PKCε and PKA, including
those that prevent membrane translocation of these
kinases, prevented the PAR2-induced sensitization of
TRPV1-dependent Ca2+ signalling, TRPV1 currents and
TRPV1 thermal hyperalgesia. These results are supported
by the observation that PAR2 agonists phosphorylate
TRPV1 in HEK 293 cells (Amadesi et al. 2004). Our
observation that PKCε makes an important contribution
to PAR2-induced sensitization of TRPV1 is in agreement
with the report that PKCε antagonists suppress the effects
of PAR2 agonists on TRPV1 Ca2+ signalling and TRPV1
currents (Amadesi et al. 2004; Dai et al. 2004). However,
our results extend this report by showing that PAR2
activates a specific PKC isozyme, and by demonstrating
a major role for both PKCε and PKA in PAR2-induced
thermal hyperalgesia.
The precise signal transduction pathway by which PAR2
activates PKCε and PKA to sensitize TRPV1 remains
to be elucidated. PKCε and PKA can both directly
phosphorylate TRPV1 (Bhave et al. 2002; Numazaki et al.
2002; Mohapatra & Nau, 2003). However, after activation
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of PAR2, we do not know if PKCε and PKA regulate
TRPV1 in an additive or synergistic manner, or whether
one pathway is upstream of the other. When administered
separately, we observed that PKCε and PKA inhibitors
almost completely prevented PAR2-induced sensitization
of TRPV1 Ca2+ signals and currents. Moreover, PKCε
and PKA inhibitors both prevented PAR2-induced thermal
hyperalgesia at later times (> 30 min). Together, these
results suggest the activation of tandem and possibly
redundant PKCε and PKA pathways. However, at earlier
times (< 30 min), PKCε and PKA inhibitors, when
given separately, did not prevent PAR2-induced thermal
hyperalgesia. Thus, the relative contributions of PKCε
and PKA may vary with time after activating PAR2. This
possibility is supported by the identification of a novel
cAMP/PKCε signalling pathway that is responsible for the
long-lasting latent susceptibility to hyperalgesia induced
by an acute inflammatory stimulus (Parada et al. 2005)
where an upstream release of cAMP and activation of
the guanine exchange factor Epac, but not of PKA, are
required to activate downstream PKCε (Hucho et al.
2005). Although our observations that PKA inhibitors
prevented the PAR2-induced sensitization of TRPV1
suggest a distinct role for PKA, in addition to the
contribution of PKCε, further experiments are required to
define the relative roles of these kinases at different times
after activation of PAR2.
In addition to the direct phosphorylation of TRPV1
by PKCε and PKA, other mechanisms may account for
PAR2-induced sensitization of this channel. PAR2 agonists
may also activate other second messenger kinases, such
as protein kinase D, a substrate for PKCε (Rey et al. 2004;
Wang et al. 2004) that can also phosphorylate and sensitize
TRPV1 (Rey et al. 2004; Wang et al. 2004). Furthermore,
PAR2 agonists could regulate the subcellular distribution of
TRPV1 rather than affecting gating of the channel. Indeed,
phorbol esters, agonists of the metabotropic glutamate
receptor and nerve growth factor sensitize neurons by
promoting trafficking of TRPV1 to the plasma membrane
(Morenilla-Palao et al. 2004; Zhang et al. 2005). These
possibilities remain to be examined, and the existence of
other mechanisms cannot be excluded.
Further studies are required to define the physiological
relevance of PAR2-induced hyperalgesia. In the present
investigation, we studied the effects of a synthetic agonist,
PAR2-AP, on thermal hyperalgesia. However, we have
previously reported that proteases such as tryptase and
trypsin similarly cause hyperalgesia by activating PAR2
(Vergnolle et al. 2001). Agents that degranulate mast
cells also induce hyperalgesia by a PAR2-dependent
mechanism (Vergnolle et al. 2001). Although tryptase
may mediate these effects, experiments with tryptase
inhibitors are required to confirm this possibility.
Extrapancreatic trypsins, such as trypsin IV, can activate
PAR2 (Cottrell et al. 2004), but their role in pain
transmission remains to be defined. In the present
study, we observed that PAR2-AP-induced thermal
hyperalgesia was sustained for 2 h, and we have previously
reported detectable hyperalgesia 24 h after PAR2 activation
(Vergnolle et al. 2001). Although our results suggest that
PKCε and PKA account for hyperalgesia at up to 120 min
after activation, different mechanisms may mediate
hyperalgesia at later times. Proteases activate PAR2 in a
catalytic and irreversible manner; once the receptor is
cleaved the exposed tethered ligand is always available
to activate PAR2. Receptor phosphorylation by G protein
receptor kinases and interaction with β-arrestins serve to
uncouple receptors from heterotrimeric G proteins and
desensitize G protein signalling (Bohm et al. 1996; Dery
et al. 1999). However, β-arrestins also mediate receptor
endocytosis and are scaffolds for mitogen-activated
protein kinases, which permits internalized PAR2 to
continue to signal through this pathway (DeFea et al. 2000).
The contribution of β-arrestins and mitogen-activated
protein kinases to sustained hyperalgesia remains to be
defined. Eventually, PAR2 is targeted for degradation in
lysosomes by a ubiquitin-mediated mechanism, which
irrevocably terminates signalling (Jacob et al. 2005).
In cell lines, resensitization of responses to proteases
requires synthesis of new receptors and mobilization of
prominent stores of PAR2 from the Golgi apparatus.
We have shown that PAR2-AP causes redistribution
of β-arrestin1-EGFP from the cytosol to the plasma
membrane, followed by translocation of PAR2-EGFP and
β-arrestin1-EGFP from the plasma membrane to endo-
somes of DRG neurons (S. Amadesi & N. W. Bunnett,
unpublished observations). However, the mechanisms of
resensitization of PAR2 in neurons, which may be required
for the sustained hyperalgesic effects of PAR2 agonists, are
completely unknown.
Together, our results further clarify the signalling
pathways by which PAR2 regulates TRPV1 to induce
hyperalgesia. We used a combination of experimental
approaches, including localization of kinases in DRG,
analysis of the subcellular distribution of PKCε and PKAC,
measurement of TRPV1 mediated Ca2+ signalling and
currents, and behavioural studies in conscious animals, to
reveal a major role of PKCε and PKA in PAR2 signalling and
PAR2-induced sensitization of TRPV1. An understanding
of the mechanisms by which proteases that activate PAR2
sensitize ion channels such as TRPV1 is important for the
development of novel therapies to treat pain.
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